BioMarin Pharmaceutical (NASDAQ:BMRN) will release its earnings data after the market closes on Thursday, February 22nd. Analysts expect BioMarin Pharmaceutical to post earnings of ($0.27) per share for the quarter.
BioMarin Pharmaceutical (BMRN) opened at $84.54 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.81 and a current ratio of 4.91. BioMarin Pharmaceutical has a one year low of $78.50 and a one year high of $100.51. The firm has a market cap of $14,850.00, a price-to-earnings ratio of -101.86 and a beta of 1.71.
A number of research analysts recently weighed in on BMRN shares. JPMorgan Chase & Co. lowered their target price on shares of BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating on the stock in a research note on Wednesday, January 24th. BidaskClub cut shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 20th. Zacks Investment Research upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research note on Tuesday, January 16th. Wedbush restated a “neutral” rating and set a $108.00 target price on shares of BioMarin Pharmaceutical in a research note on Wednesday, November 15th. Finally, BMO Capital Markets lifted their target price on shares of BioMarin Pharmaceutical from $117.00 to $119.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. BioMarin Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $111.60.
ILLEGAL ACTIVITY WARNING: “BioMarin Pharmaceutical (BMRN) to Release Earnings on Thursday” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/15/biomarin-pharmaceutical-bmrn-to-release-earnings-on-thursday.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.